Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial
| Autor: | Wang, Hui *, He, Qiang *, Zhao, Rongrong *, Xie, Linna *, Ma, Ji *, Liu, Cong *, Lu, Ke *, Wei, Haichen *, Liu, Dan *, Xing, Lijie *, Deng, Xiuzhi *, Sun, Zhongliang *, Chu, Xiaoxia *, Gao, Na *, Zhong, Yuping *, Sun, Yanhua *, Zhang, Haiyan *, Zhang, Hao *, Xu, Wenwei *, Li, Zengjun * |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:11962-11963 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|